Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 11, 2025, details the outcomes of Trevi Therapeutics, Inc.'s 2025 Annual Meeting of Stockholders. The filing addresses corporate governance matters, including the election of directors, ratification of auditors, executive compensation votes, and amendments to equity incentive plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting results rather than financial performance data.
Material Changes and Voting Results
- Director Elections: Stockholders elected Jennifer Good and Anne VanLent as Class III directors for terms expiring in 2028. Jennifer Good received 78,827,140 votes for, while Anne VanLent received 62,868,529 votes for.
- Stock Incentive Plan Amendment: Stockholders approved an amendment to the 2019 Stock Incentive Plan, increasing the number of shares available for issuance by 6,000,000 shares. The proposal received 78,703,357 votes for.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 88,898,357 votes for.
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 78,346,572 votes for. Additionally, stockholders voted to hold future advisory compensation votes annually (77,512,558 votes for the 1-year option).
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. The document is limited to reporting the results of the stockholder vote and the execution of the approved plan amendment.
Key Facts for Investor Verification
- Verify the impact of the 6,000,000 share increase in the 2019 Stock Incentive Plan on potential future dilution.
- Review the definitive proxy statement filed on April 29, 2025, for detailed terms of the plan amendment and director biographies.
- Confirm the composition of the Board of Directors following the election of Jennifer Good and Anne VanLent.
- Note that the company intends to conduct annual "say-on-pay" advisory votes based on the stockholder recommendation.